Efficacy of abiraterone acetate in castration‐resistant metastatic prostate cancer: A real‐world data analysis

Oyman, Abdilkerim; Başak, Mustafa; Özçelik, Melike; Özyükseler, Deniz Tataroğlu; Işık, Selver; Yıldırım, Mehmet

doi:10.1111/ajco.13426

Cited by 5 publications

(3 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The median OS was 17.3 months in all patients, 12.7 months in the CT-naive group, and 29.4 months in the post-CT groups (p = 0.236). While the numerical superiority in the results of our study was in patients who received pre-CT AA, the results of Oyman et al were in favor of post-CT AA 12 . Marret et al evaluated the efficacy of AA in 93 patients with mCRPC; the median duration of treatment with AA was 12.7 months and 7.5 months; median OS was 36.4 months and 13.4 months in pre-docetaxel (n = 33) and post-docetaxel (n = 58) settings, respectively.…”

Section: Discussioncontrasting

confidence: 79%

Comparison of real-life data of abiraterone acetate and enzalutamide in metastatic castration-resistant prostate cancer

Demirci

Bilir

Gülbağcı

et al. 2021

Sci Rep

View full text Add to dashboard Cite

To compare enzalutamide (E) and abiraterone acetate (AA) in terms of efficacy, survival and to characterize prognostic factors affecting survival in metastatic castration-resistant prostate cancer (mCRPC) patients. A total of 250 patients treated with E or AA in 5 centers were included. The number of patients with no prostate specific antigen (PSA) decline was higher in the AA group than that in the E group, and the proportion of patients with a PSA decline of ≥ 50% was higher in the E group (p = 0.020). Radiological progression free survival (rPFS) and overall survival (OS) were significantly longer in the E group when compared to that in the AA group (p < 0.001 and p = 0.027, respectively). In the E group, rPFS was significantly longer than that in the AA group in both pre- and post-docetaxel settings (p = 0.010 and p = 0.003, respectively). OS was similar in the pre-docetaxel setting; but in the post-docetaxel setting, E group had a significantly longer OS than the AA group (p = 0.021). In the multivariate analysis performed in the whole patient group, we found that good prognostic factors for rPFS were E treatment, being ≥ 75 years and a PSA decline of ≥ 50% while there was no factor affecting OS. With longer OS and PFS, E seems to be more suitable for mCRPC patients in the post-docetaxel setting than AA.

show abstract

Section: Discussioncontrasting

confidence: 79%

Comparison of real-life data of abiraterone acetate and enzalutamide in metastatic castration-resistant prostate cancer

Demirci

Bilir

Gülbağcı

et al. 2021

Sci Rep

View full text Add to dashboard Cite

show abstract

“…The median OS was 17.3 months in all patients, 12.7 months in the CTnaive group, and 29.4 months in the post-CT groups (p=0.236). While the numerical superiority in the results of our study was in patients who received pre-CT AA, the results of Oyman et al were in favor of post-CT AA 12 . Marret et al evaluated the e cacy of AA in 93 patients with mCRPC; the median duration of treatment with AA was 12.7 months and 7.5 months; median OS was 36.4 months and 13.4 months in pre-docetaxel (n=33) and post-docetaxel (n=58) settings, respectively.…”

Section: Discussioncontrasting

confidence: 79%

Comparison of the oncological outcomes of abiraterone acetate and enzalutamide in metastatic castration-resistant prostate cancer: A multicenter real-life data

Demirci¹,

Bilir²,

Gülbağcı³

et al. 2021

Preprint

View full text Add to dashboard Cite

Background: To compare enzalutamide (E) and abiraterone acetate (AA) in terms of efficacy, survival and prognostic factors affecting survival in metastatic castration-resistant prostate cancer (mCRPC) patients. Methods: A total of 250 patients treated with E or AA in 5 centers were included.Results: The number of patients with no prostate specific antigen (PSA) decline was higher in the AA group than that in the E group, and the proportion of patients with a PSA decline of ≥50% was higher in the E group (p = 0.020). The rate of progression in the AA group (82.2%) was significantly higher than that in the E group (p <0.001). Radiological progression free survival (rPFS) and overall survival (OS) were significantly longer in the E group when compared to that in the AA group (p <0.001 and p = 0.027, respectively). In the E group, rPFS was significantly longer than that in the AA group in both pre- and post-docetaxel settings (p=0.010 and p=0.003, respectively). OS was similar in the pre-docetaxel setting; but in the post-docetaxel setting, E group had a significantly longer OS than the AA group(p=0.021). In the multivariate analysis performed in the whole patient group, we found that good prognostic factors for rPFS were E treatment, being ≥75 years and a PSA decline of ≥50% while there was no factor affecting OS. Conclusion: With longer OS and PFS, E seems to be more suitable for mCRPC patients in the post-docetaxel setting than AA.

show abstract

“…PSA-PFS was 7.4 months (range 4.6–13.4) in the chemotherapy-naïve group and 9.1 months (range 4.8–13.1) in the post-chemotherapy group ( p = 0.843). AA was considered as an effective and reliable agent in this study [ 24 ].…”

Section: Review Outcomesmentioning

confidence: 99%

Novel hormonal therapies in the management of advanced prostate cancer: extrapolating Asian findings to Southeast Asia

et al. 2023

View full text Add to dashboard Cite

There is a paucity of information on the use of novel hormonal agents in Southeast Asian patients. We reviewed the clinical roles of novel hormonal therapy (NHT), namely abiraterone acetate (AA), enzalutamide, apalutamide and darolutamide, in the management of advanced prostate cancer, and data on its use in Asian patients, in order to extrapolate these findings to the Southeast Asian patient population. There are some differences in the molecular features between the NHTs, which influenced their respective permeabilities through the blood–brain barrier. The Asian sub-analyses of the landmark studies of each NHT were limited. The primary endpoints of the Asian sub-analyses generally reflect the efficacy outcomes of the respective landmark study. Hypertension, fatigue, musculoskeletal disorders, rash, and hot flushes were among the common toxicities observed in Asian patients. Real-world data on AA in the Asian setting is favourable, but data is limited for enzalutamide, apalutamide and darolutamide. Based on the sub-analyses and real-world data, the efficacy and safety of NHTs in the Asian patients showed a similar trend to the respective landmark studies. The lack of clinical trials in the Southeast Asian region hampers the ability to make a robust conclusion on any specific efficacy or safety differences that may be present; clinicians must assume that the broader Asian sub-analyses and real-world data reflects Southeast Asian patients' outcomes.

show abstract

Efficacy of abiraterone acetate in castration‐resistant metastatic prostate cancer: A real‐world data analysis

Abstract: Treatment algorithms of metastatic castrationresistant prostate cancer were expanded with drugs targeting the androgen signaling pathway. The aim of this study was to evaluate the efficacy of abiraterone in patients with castration-resistant metastatic prostate cancer.

Cited by 5 publications

References 20 publications

Comparison of real-life data of abiraterone acetate and enzalutamide in metastatic castration-resistant prostate cancer

Comparison of real-life data of abiraterone acetate and enzalutamide in metastatic castration-resistant prostate cancer

Comparison of the oncological outcomes of abiraterone acetate and enzalutamide in metastatic castration-resistant prostate cancer: A multicenter real-life data

Novel hormonal therapies in the management of advanced prostate cancer: extrapolating Asian findings to Southeast Asia

Contact Info

Product

Resources

About